A Phase 2 interventional study of GWP42003 200 mg/day Dose and GWP42003 400 mg/day Dose in Fatty Liver, sponsored by GW Research Ltd. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-08.
Sponsored by GW Research Ltd (part of Jazz Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Fatty Liver with a site in United Kingdom — 16 open to participants now, 19 under way, 4 of them phase 3. Fatty Liver · United Kingdom.
Among the 44 studies in Fatty Liver with a site in United Kingdom, this one is the 27th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2011, is one of 9 in phase 2, and was the 5th registered.
664 studies on the registry are indexed under Fatty Liver; 186 are open to participants now.
Browse Fatty Liver studies →16 of the 44 studies in Fatty Liver with a site in United Kingdom are open now. Recruiting first, the newest first:
Tangram Therapeutics Plc · Sites in United Kingdom
Ages 18–70 · Healthy volunteers
Eli Lilly and Company · Sites in United Kingdom, United States, Argentina and 31 more countries
Ages 18+
Queen Mary University of London · Sites in United Kingdom
Ages 45–65 · Healthy volunteers
Novo Nordisk A/S · Sites in United Kingdom
Ages 18–64
University of Oxford · Sites in United Kingdom
Ages 18+ · Women only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 12 · Phase 3 7 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 60 across 433 interventional studies indexed under Fatty Liver.
Median enrollment 81 across the 34 interventional studies, 89 across the 10 observational. Of the 22 that completed or were terminated, 11 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under GW Research Ltd, one of the names counted as Jazz Pharmaceuticals. Under that name alone:
GW Research Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.
Jazz Pharmaceuticals has 2 studies filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
5 of the studies in Fatty Liver with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013916Queen Mary University of LondonFructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH) | 2027-04-01 |
| NCT06920316St. George's Hospital, LondonDigital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | 2027-05 |
| NCT06836609Regeneron PharmaceuticalsA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) | 2027-08-17 |
| NCT06891365Novo Nordisk A/SMultiple Dose Study for a New Medication to Potentially Treat Liver Diseases | 2027-10-11 |
| NCT06613698GlaxoSmithKlineA Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease | 2027-11-26 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies in Fatty Liver with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of GWP42003 on liver triglyceride (liver fat) in participants with fatty liver disease (FLD).
This study was conducted as a 10-week (eight-week treatment period and one-week safety follow-up), randomized, partially-blind study that evaluated the effect of GWP42003 in participants with raised liver triglycerides (liver fat ≥5%). Participants were clinically diagnosed with FLD and had liver fat levels ≥5% as measured by Magnetic Resonance Imaging/ Magnetic Resonance Scanning (MRI/MRS), or were willing to undergo MRI/MRS scan at the screening visit to confirm a liver fat content of ≥5%. Eligible participants entered the study at a screening visit (Day -10 to -2) and then returned for a fasted baseline visit (Day 1), a mid-treatment visit (Day 29) and an end of treatment visit (Day 57). Safety follow-up telephone calls took place throughout the treatment period up to Day 64 after completion of treatment or seven days after date of last dose/withdrawal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants self-administered one x 100 mg GWP42003 capsule twice daily for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]).
Drug: GWP42003 200 mg/day Dose
Participants self-administered two x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]).
Drug: GWP42003 400 mg/day Dose
Participants self-administered four x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]).
Drug: GWP42003 800 mg/day Dose
Participants self-administered one, two or four placebo capsules twice daily, for 8 weeks (the first dose was 30 minutes before breakfast \[fasted\] and the second was 30 minutes before the evening meal \[typically 12 hours apart\]). Each capsule exactly matched the GWP42003 capsules in terms of appearance, size, smell and taste.
Drug: Placebo
Drug page: Cannabidiol
GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
Also known as: Cannabidiol, CBD
Drug page: Cannabidiol
GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
Also known as: Cannabidiol, CBD
Drug page: Cannabidiol
GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
Also known as: Cannabidiol, CBD
Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
Also known as: Placebo control
Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels
Liver triglyceride levels were measured by Magnetic Resonance Imaging/Magnetic Resonance Scanning and the percent change from baseline to EOT in group mean levels was investigated. A reduction from baseline, that is, a negative value, indicates an improvement in condition.
Time frame: Baseline to EOT (Day 57) or Early Termination (ET)
Change From Baseline To The EOT In Mean Serum Total Cholesterol Levels
A fasting blood sample was taken for the measurement of serum total cholesterol. A reduction from baseline, that is, a negative value, indicates an improvement in condition.
Time frame: Baseline to EOT (Day 57) or ET
Change From Baseline To The EOT In Mean Serum High Density Lipoprotein (HDL)-Cholesterol(C) Levels
A fasting blood sample was obtained for the measurement of HDL-C. An increase from baseline, that is, a positive value, indicates an improvement in condition.
Time frame: Baseline to EOT (Day 57) or ET
Change From Baseline To The EOT In Mean Serum Low-Density Lipoprotein (LDL)-C Levels
A fasting blood sample was obtained for the measurement of LDL-C. An increase from baseline, that is, a positive value, indicates an improvement in condition.
Time frame: Baseline to EOT (Day 57) or ET
Change From Baseline To The EOT In Mean Serum HDL: Low Density Lipoprotein (LDL)-Cholesterol (C) Ratio
A fasting blood sample was obtained for the measurement of HDL-C and LDL-C, allowing the HDL:LDL cholesterol ratio to be calculated. An increase from baseline, that is, a positive value, indicates an improvement in condition.
Time frame: Baseline to EOT (Day 57) or ET
Change From Baseline To The EOT In Mean Serum Triglyceride Levels
A fasting blood sample was obtained for the measurement of serum triglycerides. A reduction from baseline, that is, a negative value, indicates an improvement in condition.
Time frame: Baseline to EOT (Day 57) or ET
| Milestone | GWP42003 200 Milligram (mg)/Day Dose | GWP42003 400 mg/Day Dose | GWP42003 800 mg/Day Dose | Placebo |
|---|---|---|---|---|
| Started | 7 | 6 | 7 | 5 |
| Received at least 1 dose of study drug | 7 | 6 | 7 | 5 |
| Intent to treat (itt) analysis set | 7 | 6 | 7 | 5 |
| Completed | 6 | 6 | 5 | 4 |
| Not completed | 1 | 0 | 2 | 1 |
| Withdrew: Adverse event | 1 | 0 | 2 | 1 |
Liver triglyceride levels were measured by Magnetic Resonance Imaging/Magnetic Resonance Scanning and the percent change from baseline to EOT in group mean levels was investigated. A reduction from baseline, that is, a negative value, indicates an improvement in condition.
| percentage change | GWP42003 200 mg/Day Dose | GWP42003 400 mg/Day Dose | GWP42003 800 mg/Day Dose | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels | -0.68 ± 4.97 | -0.28 ± 8.60 | 0.65 ± 5.28 | 6.36 ± 17.97 |
A fasting blood sample was taken for the measurement of serum total cholesterol. A reduction from baseline, that is, a negative value, indicates an improvement in condition.
| millimole (mmol)/l | GWP42003 200 mg/Day Dose | GWP42003 400 mg/Day Dose | GWP42003 800 mg/Day Dose | Placebo |
|---|---|---|---|---|
| Change From Baseline To The EOT In Mean Serum Total Cholesterol Levels | 0.07 ± 0.76 | 0.03 ± 0.51 | -0.14 ± 0.31 | -0.62 ± 1.00 |
A fasting blood sample was obtained for the measurement of HDL-C. An increase from baseline, that is, a positive value, indicates an improvement in condition.
| mmol/l | GWP42003 200 mg/Day Dose | GWP42003 400 mg/Day Dose | GWP42003 800 mg/Day Dose | Placebo |
|---|---|---|---|---|
| Change From Baseline To The EOT In Mean Serum High Density Lipoprotein (HDL)-Cholesterol(C) Levels | 0.07 ± 0.15 | 0.08 ± 0.15 | 0.06 ± 0.17 | -0.14 ± 0.23 |
A fasting blood sample was obtained for the measurement of LDL-C. An increase from baseline, that is, a positive value, indicates an improvement in condition.
| mmol/l | GWP42003 200 mg/Day Dose | GWP42003 400 mg/Day Dose | GWP42003 800 mg/Day Dose | Placebo |
|---|---|---|---|---|
| Change From Baseline To The EOT In Mean Serum Low-Density Lipoprotein (LDL)-C Levels | 0.11 ± 0.631 | 0.08 ± 0.407 | 0.00 ± 0.432 | -0.34 ± 0.737 |
A fasting blood sample was obtained for the measurement of HDL-C and LDL-C, allowing the HDL:LDL cholesterol ratio to be calculated. An increase from baseline, that is, a positive value, indicates an improvement in condition.
| change in ratio | GWP42003 200 mg/Day Dose | GWP42003 400 mg/Day Dose | GWP42003 800 mg/Day Dose | Placebo |
|---|---|---|---|---|
| Change From Baseline To The EOT In Mean Serum HDL: Low Density Lipoprotein (LDL)-Cholesterol (C) Ratio | -0.02 ± 0.13 | -0.00 ± 0.08 | 0.03 ± 0.09 | 0.01 ± 0.06 |
A fasting blood sample was obtained for the measurement of serum triglycerides. A reduction from baseline, that is, a negative value, indicates an improvement in condition.
| mmol/l | GWP42003 200 mg/Day Dose | GWP42003 400 mg/Day Dose | GWP42003 800 mg/Day Dose | Placebo |
|---|---|---|---|---|
| Change From Baseline To The EOT In Mean Serum Triglyceride Levels | -0.40 ± 1.05 | -0.29 ± 0.82 | -0.50 ± 1.16 | -0.28 ± 0.39 |
Collected over Day 1 through Day 77. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003 200 mg/Day Dose | — | 0/7 (0%) | 6/7 (85.7%) |
| GWP42003 400 mg/Day Dose | — | 0/6 (0%) | 5/6 (83.3%) |
| 800 mg GWP42003 | — | 0/7 (0%) | 7/7 (100%) |
| Placebo | — | 0/5 (0%) | 5/5 (100%) |
| Event | GWP42003 200 mg/Day Dose | GWP42003 400 mg/Day Dose | 800 mg GWP42003 | Placebo |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/7 | 3/6 | 5/7 | 0/5 |
| HeadacheNervous system disorders | 1/7 | 3/6 | 2/7 | 0/5 |
| Abdominal distensionGastrointestinal disorders | 0/7 | 1/6 | 1/7 | 1/5 |
| Abdominal painGastrointestinal disorders | 0/7 | 1/6 | 1/7 | 1/5 |
| Abnormal faecesGastrointestinal disorders | 0/7 | 0/6 | 0/7 | 1/5 |
| Change of bowel habitGastrointestinal disorders | 0/7 | 0/6 | 0/7 | 1/5 |
| ConstipationGastrointestinal disorders | 0/7 | 0/6 | 0/7 | 1/5 |
| FlatulenceGastrointestinal disorders | 0/7 | 0/6 | 0/7 | 1/5 |
| NauseaGastrointestinal disorders | 1/7 | 1/6 | 0/7 | 1/5 |
| Seasonal allergyImmune system disorders | 0/7 | 1/6 | 0/7 | 1/5 |
Safety Analysis Set: Participants who received at least 1 dose of investigational medicinal product (IMP); analyzed as per actual treatment received.
| Age, Continuous(years) | GWP42003 200 mg/Day Dose | GWP42003 400 mg/Day Dose | GWP42003 800 mg/Day Dose | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 40.69 ± 14.62 | 49.08 ± 7.72 | 46.90 ± 12.57 | 50.41 ± 18.41 | 46.39 ± 13.29 |
| Sex: Female, Male(Participants) | GWP42003 200 mg/Day Dose | GWP42003 400 mg/Day Dose | GWP42003 800 mg/Day Dose | Placebo | Total |
|---|---|---|---|---|---|
| Female | 5 | 2 | 2 | 4 | 13 |
| Male | 2 | 4 | 5 | 1 | 12 |
Ran from May 2011 to primary completion in Jul 2012, 14 months.
Results were first posted in Jan 2014, 1 year 6 months after primary completion.
Of 41 phase 2 interventional studies under Fatty Liver, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol